Meredith Manning
Chief Commercial Officer
Meredith S. Manning joined Genetix in 2026 as Chief Commercial Officer, where she leads commercial strategy and execution for the company’s portfolio of FDA-approved, one-time gene addition cell therapies. She has more than 25 years of experience in the biopharmaceutical industry, spanning rare disease, hematology, oncology, and specialty markets, with expertise in market access, launch execution, and global expansion.
Before joining Genetix, Meredith served as Chief Commercial Officer at Soleno Therapeutics, where she built the commercial organization from inception and led the U.S. launch of the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Prior to that, she served as President, The Americas, at PharmaEssentia Corporation, where she built the U.S. organization, supported the company through FDA approval, and led the US commercial launch of a novel treatment for a rare blood cancer. She also served as Chief Commercial Officer at resTORbio.
Earlier in her career, Meredith led a $3 billion global hemophilia portfolio at Shire (formerly Baxter/Baxalta) and held roles at Pfizer.
Meredith holds an MBA from the University of Chicago Booth School of Business and a BA in political science from the Colorado College.
